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Summary. One of the most important challenges in today’s
cardiology is prevention of sudden cardiac death in high
risk patients with coronary artery disease (CAD). Sustained
hemodynamically tolerated ventricular tachycardia (HTVT)
comprises up to 30% of all cases of monomorphic ventricular
tachycardia in patients with CAD. While there is a consen-
sus on treatment of hemodynamically unstable sustained
ventricular tachycardia in patients with CAD, some contro-
versies regarding the proper treatment of HTVT exist. We
re-examined existing clinical evidence, controversies and
current guidelines on the treatment of HTVT in patients
with CAD and demonstrated that compared to implantable
cardioverter-defibrillator, amiodarone is not an acceptable
therapeutic option in patients with ischemic heart disease
who suffer from HTVT.
Key Words. coronary artery disease, ventricular tachycar-
dia, implantable defibrillators, amiodarone, sudden cardiac
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Introduction
One of the most important challenges nowadays is pre-
vention of sudden cardiac death (SCD) in high risk pa-
tients with coronary artery disease (CAD) [1]. There is
some inconsistent evidence supporting potential bene-
fit of amiodarone in the prevention of SCD in high risk
post myocardial infarction (MI) patients [2]. Develop-
ment of implantable cardioverter-defibrillators (ICD)
has been a dramatic advancement in the management
of patients with ventricular tachycardia (VT). Several
reviews have assessed the current evidence on superi-
ority of ICD in the prevention of SCD in various patient
populations with spontaneous sustained monomorphic
ventricular tachycardia (MMVT) compared to amio-
darone, and, based on these studies, AHA/ACC guide-
line has given ICD a class I indication with level of evi-
dence: B in patients with spontaneous sustained VT (ir-
respective of hemodynamic status during arrhythmia)
in association with structural heart disease [3,4]. While
there is a consensus on treatment of hemodynamically
unstable sustained VT in patients with CAD, some
controversies exist regarding the proper treatment of
HTVT [1,4]. This review intends to re-examine existing
clinical evidence, controversies and current guidelines
on the treatment of HTVT in patients with CAD.
Prevalence of MMVT and HTVT in patients
with CAD and its impact on survival
Late sustained MMVT occurs in 3–5% [5] of patients
after an acute MI and has been associated with a poor
prognosis (relative risk of mortality: 2.6 to 9.1 accord-
ing to different studies) when compared to those with-
out a ventricular arrhythmia [6]. Several studies have
assessed the effect of MMVT on survival of patients
with CAD [6–10,13]. The reported annual mortality of
these patients varied from 5% (in those with a left ven-
tricular ejection fraction [LVEF] >50%) [9] to more
than 40% [10] in patients with LV dysfunction. Newby
et al. [7] have examined the incidence and impact of
MMVT on survival of 40,895 post MI patients in the
“Global Use of Streptokinase t-PA for Occluded Coro-
nary Arteries” (GUSTO)-I trial. In GUSTO-I the in-
cidence of late sustained MMVT was 3.5%. The over-
all one year mortality in 30 day survivors in the late
VT group was 24.7% (mean LVEF = 46%) compared
to 2.7% in patients without ventricular arrhythmias
(mean LVEF = 52%). Al-Khatib et al. [11] have re-
cently assessed the effect of late MMVT on survival
of 15,042 post MI patients participating in GUSTO-III
trial which confirmed the above mentioned findings of
GUSTO-I trial. These results were confirmed also by a
study on 26,416 patients with acute coronary syndrome
[12]. The prevalence of late MMVT in these patients
was 2.1% (lower than post MI patients in GUSTO-I and
III), however the hazard ratio (HR) was comparable
(HR = 5, 95% Confidence Interval = 3.8–6.5) to the
GUSTO-I and III studies. It is worth to mention that
in GUSTO I and III the mortality of patients with late
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sustained MMVT was higher compared to patients with
late VF. This is in accordance to the CARE group re-
sults [14] which showed that the probability of appro-
priate ICD discharge is two times higher in patients
with sustained MMVT compared to those with aborted
SCD and VF.
A recently published guideline [1] has recommended
amiodarone and beta blocker therapy as a class IIa in-
dication and ICD, along with ablation and surgery, as
class IIb recommendation for the treatment of patients
with HTVT. The above mentioned statement could only
be accepted if one assumes that the mortality in HTVT
is significantly lower than more severely symptomatic
VTs and that amiodarone therapy is equal or superior
to ICD with respect to prevention of SCD in this par-
ticular group of patients.
HTVT comprises up to 30% of all cases of MMVT in
patients with CAD [15,16]. Several studies have exam-
ined the effect of HTVT on survival compared to more
severely symptomatic VT. Although Sarter et al. have
suggested a better prognosis for HTVT [17] (however,
some debates exist on their data as 64% of deaths in
their study were non-sudden either due to perioper-
ative death, recurrent infarction or progressive heart
failure. Thirty seven percent of patients were treated
with VT surgery with a perioperative mortality of 20%.
This surgery improved the outcome in patients who sur-
vived the operation and gives an inaccurate estimate of
the risk of SCD in those who survived. In addition they
found that longer VT cycle length, which one could ex-
pect to be associated with more benign symptoms, is
related to a higher mortality [18]). Others showed that
the risk is similar to patients with more severely symp-
tomatic VT. Raitt et al. performed a retrospective sub-
group analysis of the AVID registry [15] and showed
that the absence of symptoms with sustained VT does
not predict a benign prognosis (see below). Olson et al.
assessed the predictors of SCD in 122 patient followed
for an average of 19.5 months [18] and showed that the
rate of SCD is not affected by presence or absence of
symptoms during MMVT.
Multiple VTs (including very rapid, poorly tolerated
VTs) are commonly induced during electrophysiologi-
cal (EP) testing in patients with stable VT [19]. Hav-
ing these in mind, HTVT actually is a marker of sub-
strates for re-entrant ventricular arrhythmias which
may causes more malignant ventricular arrhythmias
during long term follow up. Based on available data,
ICD therapy decreases all-cause mortality in CAD pa-
tients with sustained VT, and with respect to the above
mentioned findings, could also decrease the mortality in
patients with HTVT. Patients with HTVT are at high
risk for sudden arrhythmic death, and presumably it is
not the recurrence of the stable VT that leads to SCD
but a more malignant ventricular arrhythmias. Bocker
et al. studied the natural course of 50 patients (82%,
CAD) with HTVT who received an ICD [20]. They
showed that during mean follow up of 17 months, 33 pa-
tients (66%) had 3861 episodes of ventricular tachycar-
dia which is comparable to other studies in patients with
sustained MMVT [14,21]. Ninety one percent of these
episodes were terminated by antitachycardia pacing.
Eleven patients (22%) had episodes of potentially life-
threatening fast VT (CL <250 ms) during follow up
period. In the AVID registry [18] (mean follow up of
16.9 months) the mortality rate for patients with synco-
pal VT was 21.2% and for asymptomatic VT was 19.7%
(P = NS). Had the ICD not been implanted in the
Bocker study, their patients would have had at least
the same mortality as in the AVID registry. It is worth
to mention that in the Bocker study (like the Electro-
physiologic Study Versus Electromagnetic Monitoring
trial) [22] EP studies failed to predict which patient
would have more rapid VT in the follow up. In conclu-
sion, currently available data depict that HTVT nega-
tively affects the survival of post MI patients as more
severely symptomatic VT does.
Finally, epidemiological studies have consistently
shown an inverse relationship between LVEF and sur-
vival in patients with CAD [23]. When LVEF decreases
below 35–40%, the risk of sudden and non-sudden car-
diac death rises sharply. In patients who have an LVEF
<40%, the mortality rate at 2 years after infarction is
21.5% compared with 7.6% in patients with an LVEF
>40% [23–27].
A subgroup analysis of AVID showed that patients
with LVEF >35% failed to benefit from ICD [28]. How-
ever, the AVID trial design had a low power to detect
an ICD benefit in this small subgroup of patients dur-
ing short observation period which was also terminated
prematurely. These factors prevented the ICD benefit
from reaching statistical significance in this small sub-
group of patients. As we indicate below (see: Do we
need a prospective clinical trial comparing ICDs with
empiric or EP guided amiodarone therapy in CAD pa-
tients with HTVT) if we want to conduct an AVID like
trial in patients with HTVT and preserved LV function
one would need a sample size of 1072 patients followed
for three years. Hence, had the follow up period of the
AVID trial been continued in an adequate number of
patients for a sufficient time period, ICD would have
shown its beneficial effect in these patients (see also:
Do the benefits of ICD versus Amiodarone change over
time?) In addition there is another subgroup analysis of
AVID which showed that in patients treated with an-
tiarrhythmic medications (but not those treated with
ICD) survival was strongly associated with LVEF. The
lack of statistically significant association in ICD pa-
tients might have been related to its efficacy in termi-
nating malignant VA regardless of LVEF [29].
Role of Amiodarone in the Treatment
of Patients with Sustained VT
A: Empiric Amiodarone Therapy
Secondary prevention. Amiodarone suppresses pre-
mature ventricular depolarizations and episodes of
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nonsustained VT, but, there have not been any placebo-
controlled trials on its effectiveness on sustained VT
and VF [2]. All available articles only report the out-
comes of patients with aborted sudden cardiac arrest
or recurrent VT treated with amiodarone alone or ver-
sus other antiarrhythmics. Some reports conclude that
amiodarone is as effective, and some suggest that amio-
darone is not as effective as it was shown by early
promising reports. The Cardiac Arrest in Seattle: Con-
ventional versus Amiodarone Drug Evaluation study,
the only randomized clinical trial available, showed that
amiodarone is superior to other conventional antiar-
rhythmic drugs, which we know today, increase car-
diac mortality [30]. The largest follow-up of amiodarone
treated patients [31] (589 patients with supraventricu-
lar tachycardia, 83% of whom had VT or VF), showed
that the 5-year cumulative risk of sudden death was
22% and of total mortality, 46%. The cumulative risk of
drug failure (defined as SCD, recurrence of ventricu-
lar arrhythmias, or drug withdrawal) at 5 years, was
50%. In conclusion it is difficult to reach to any definite
conclusion about the efficacy of amiodarone from these
uncontrolled reports.
Primary prevention. Fifteen randomized clinical tri-
als (5864 patients), including six in post MI patients
[32–37], were performed on amiodarone as a prophy-
laxis against SCD in moderate to high risk patients for
SCD. Two meta-analyses [37,38] of these trials showed
a 13 to 19% reduction in total mortality but the odds ra-
tio was different based on the control group: the odds
ratio for total mortality was lower in trials with “usual
care” controls (odds ratio, 0.58; 95% CI, 0.41 to 0.83;
P = .003) and in trials with active controls (odds ra-
tio, 0.73; 95% CI, 0.43 to 1.25; P = .25) than in tri-
als with placebo controls (odds ratio, 0.90; 95% CI, 0.76
to 1.06; P = .20). These two meta-analyses suggested
that amiodarone therapy reduces total mortality by be-
tween 10% (placebo-controlled trials only, P = NS) and
13–19% (all trials, P = 0.03 and P < 0.01 respectively)
in patients with moderate to high risk of sudden cardiac
death. There has been no placebo-controlled trial so far
to assess amiodarone’s effect in patients with HTVT.
Finally, the results of The Sudden Cardiac Death in
Heart Failure Trial (SCD-HeFT) confirmed the find-
ings in the above mentioned placebo-controlled studies
on amiodarone. Among patients with NYHA class II
and III congestive heart failure and an LVEF ≤35%
(23% with a history of NSVT) who were on optimal
medical therapy, amiodarone (compared to placebo) did
not show a beneficial effect on total mortality by in-
tention to treat analysis (HR = 1.06, 97.5% Confidence
Interval = 0.86–1.30, P = 0.529) [39].
B: EP-guided amiodarone therapy
Amiodarone is usually prescribed empirically (as it is
recommended by ESC taskforce on SCD). Several stud-
ies have suggested that EP-guided therapy can in-
crease the success rate of therapy with amiodarone
[40–47]. In these studies lack of inducible ventricular
arrhythmias after amiodarone therapy was associated
with a better outcome. Lack of suppression of ven-
tricular arrhythmias, slowing of the VT cycle length,
and unchanged ventricular effective refractory period
were all associated with higher long term recurrence
of ventricular arrhythmias and mortality. There are
three major setbacks in EP-guided amiodarone ther-
apy. First, the success rate for complete VT suppression
rate during EP studies varies between 10–40% in these
studies. Second, there is no standard and widely ac-
ceptedventricular stimulation protocol for assessment
of its usefulness and different protocols have been used
so far. Third, amiodarone has not been tested against
ICD in the above mentioned trials.
Schla¨pfer et al. conducted the first study aiming at a
comparison between EP-guided amiodarone and ICD
therapy in 84 consecutive post MI patients with sus-
tained MMVT [16]. Aborted SCD and syncope were
clinical presentations of the index arrhythmia in 40%
of cases and 77% of their patients were in NYHA
class = II. They showed that the outcome of the pa-
tients (including 55% with EF ≤35%) in their study
was better with ICD than EP-guided amiodarone ther-
apy. During follow up of 63 ± 30 months, total mor-
tality (and SCD) was 42% (21%) in EP-guided group
and 15% (2%) in ICD group. It is noteworthy that
their data showed that even complete suppression of
VT by EP-guided amiodarone therapy was not protec-
tive against risk of future SCD (Schla¨pfer J: Personal
communication).
C: adjunctive amiodarone in patients
with ICD
No empiric antiarrhythmic therapy (including amio-
darone) is currently indicated in patients who received
an ICD. Up to 40% of patients receiving an ICD develop
“electrical storm,” defined as two or more episodes of
VT and/or VF in a one day period [48,49]. These pa-
tients frequently receive multiple ICD shocks, which
severely impair quality of life. Intravenous followed by
oral amiodarone results in successful management and
possibly a long-term effect similar to patients who do
not have electrical storm [48,49].
The OPTIC (Optimal Pharmacological Therapy in
Implantable Cardioverter) study currently assesses
the potential benefit of antiarrhythmic medications in
reduction of ICD therapy and electrical storm. In OP-
TIC the patients are randomize to β-blocker, amio-
darone plus β-blocker, or sotalol. A sub-study of the
OPTIC study will also assess defibrillation threshold
before and after drug therapy in patients random-
ized to the above mentioned drugs [48]. Amiodarone
may have some other potential benefits in patients
with ICDs including the prevention of supraventricu-
lar tachyarrhythmias, which could cause inappropriate
ICD discharges; and the prevention of nonsustained but
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symptomatic ventricular arrhythmias. Further studies
are warranted to clarify this issue [50].
D: role of amiodarone in hybrid therapy
of HTVT
Although several studies have established the role of
catheter ablation of VT (including HTVT) as an adjunc-
tive therapy to ICD in patients with CAD who receive
frequent high voltage therapies [51–54], few have eval-
uated the role of catheter ablation plus adjunctive amio-
darone in patients with HTVT [55].
Della Bella et al. in a non-randomized prospective
study (median follow up of 41.5 months), evaluated
the outcome of catheter ablation and adjunctive amio-
darone and/or beta-blocker therapy in 124 (mean age
64 ± 9 years, with EF >30% in 2/3 of cases) post-MI
patients with HTVT (24 of whom had an ICD). The
procedure of catheter ablation was successful (defined
as termination and prevention of induction of all
clinical and inducible VTs) in 73% of patients and after
ablation 86% of patients received amiodarone and/or
a beta blocker as an adjunctive therapy. The rate of
all cause mortality and sudden cardiac death during
the study period were 12 and 2.6%, respectively [55].
However, several points merit consideration. Although
the mortality was relatively low during follow up,
the rate of recurrent VT remained high even among
patients with an initially successful procedure. Among
these patients the 1 and 3 year VT recurrence rates
were 19 and 27%, respectively. In addition, as this
study was non-randomized we cannot conclude that
this combination therapy is as effective as or superior
to ICD in patients with HTVT [55].
In conclusion, based on currently available data
[18,20,52] catheter ablation (with or without adjunc-
tive antiarrhythmic therapy) can not be recommended
as an alternative to ICD in patients with HTVT. How-
ever, in case of frequent ICD shocks, amiodarone and/or
catheter ablation should be considered as an adjunctive
treatment.
Do the benefits of ICD versus amiodarone
change over time?
A meta-analysis of the CASH, CIDS and AVID trials
showed a significant reduction in death from any cause
with ICD, hazard ratio (ICD:amiodarone) of 0.72 (95%
CI, 0.60 to 0.87; P: 0.0006) [56]. However, neither the
CIDS nor the CASH trials alone demonstrated a sig-
nificant benefit of the ICD over amiodarone. Bokhari
et al. [57] have recently published the 11 year follow
up in a subset of patients of CIDS trial. After a mean
follow-up of 5.6 ± 2.6 years in 120 patients, there were
28 deaths (47%) in the amiodarone group, compared
with 16 deaths (27%) in the ICD group (P = 0.0213).
Total mortality was 5.5% per year in the amiodarone
group versus 2.8% per year in the ICD group (hazard
ratio of amiodarone: ICD, 2.011; 95% confidence inter-
val, 1.087 to 3.721; P = 0.0261). In the amiodarone
group, 49 patients (82% of all patients) had side ef-
fects related to amiodarone, of which 30 patients (50%
of all patients) required discontinuation or dose reduc-
tion; 19 patients crossed over to ICD because of amio-
darone failure (n = 7) or side effects (n = 12) [57].
The authors showed that during long term follow up
the benefit of the ICD over amiodarone increases and
most amiodarone-treated patients eventually develop
side effects, have arrhythmia recurrences, or die. This
finding has been confirmed recently by Salukhe et al.
[58]. They estimated, from published data of 8 ma-
jor ICD trials, the cumulative benefit life-years gained
and calculated the dependency of the benefit on dura-
tion of follow-up. They found that the number of life-
years gained from one device implantation increases
with length of follow-up. Importantly, this increase is
markedly nonlinear. Within a 3-year span, the benefit
rises with the square of time (gain α t1.94, R 2 = 0.998,
P = 0.001). They concluded that the expected benefit
in life span (life-years gained) for a patient who has an
ICD is dramatically dependent on the time window over
which the benefit is assessed. It is important to consider
the effect of follow-up duration while interpreting the
results and outcome in ICD trials [58].
Concerns have recently been raised about the role
of ICD therapy in apparently stable patients with left
ventricular dysfunction several years after MI [59]. It
is widely believed that among patients with CAD as
the time passes from MI the risk of SCD, and hence,
the potential benefit of ICD over amiodarone is dimin-
ishing. Long-term follow-up of MI survivors conducted
in the 1970s and 1980s indicated that the greatest risk
of sudden death was in the initial 6 to 12 months after
infarction, particularly in high-risk subgroups such as
those with impaired ventricular function [60–62].
Wilber and his colleagues analyzed the time depen-
dence of mortality risk after MI in the MADIT II co-
hort and evaluated whether long-term survival benefit
diminished as a function of elapsed time from infarction
to ICD implantation [63]. They found that in contrast to
early reports, mortality risk in the MADIT II cohort did
not diminish as a function of time from MI; instead, it ac-
tually increased. In addition, the survival benefit associ-
ated with ICDs appears to be greater for remote MI and
remains substantial for up to ≥15 years after MI. They
also found a trend toward increasing device benefit with
remote MI although this did not reach statistical signif-
icance [63]. In conclusion the above mentioned studies
have shown that the benefit of ICD over amiodarone
increases over time (Fig. 1). This effect is observed in
both primary and secondary prevention trials.
Do we need a prospective clinical trial
comparing ICDs with empiric or EP guided
amiodarone therapy in CAD patients
with HTVT?
Although there has been no clinical trial (as a gold
standard in medical practice) specifically conducted in
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patients with HTVT, all the above mentioned data sug-
gest that CAD patients presenting with HTVT have
at least as high a total mortality rate as patients pre-
senting with more severely symptomatic VT, and that
amiodarone (empiric or EP guided) is not an appro-
priate option for treatment of patients with sustained
MMVT, and an ICD is the treatment of choice similar
to patients with unstable VT.
It is sometimes not possible and/or practical to per-
form a randomized controlled study in every subset of
patients at risk [64]. When we have enough reliable data
to calculate the risk of adverse event of interest in pa-
tients at risk, and a reliable assessment of the beneficial
effect of intervention, risk modelling may be used as an
alternative [64]. Exner and Klein have suggested that
based on available data we can extrapolate the results
of available trials with ICD and there is no need to per-
form a clinical trial in all subsets of patients at high risk
for SCD [64]. They estimated that at the completion of
the follow up period of SCD-HeFT the ICD would show
a statistically significant absolute risk reduction in to-
tal mortality (compared to placebo) of 7.3–8.6%, which
is confirmed by results of SCD-HeFT [39]. At the com-
pletion of the follow up period, ICD resulted in nearly
8% absolute risk reduction in total mortality compared
to placebo.
Suppose that we want to assess the effect of ICD vs.
amiodarone on total mortality (as primary end point)
in patients with HTVT with a clinical trial having a
3 year follow up (Inclusion is 2 years +2 years follow
up period after inclusion) and a power of 95% with no
interim analysis. We estimate that the total mortality
rate would be around 9%/year in the amiodarone group
and ICD would reduce the total annual mortality by
50% (the mode of death in patients with HTVT is ar-
rhythmic in at least 61% of cases [63–67] and ICD will
effectively terminate these arrhythmias in more than
90% of cases [68], so one can expect that ICD would
reduce the total annual mortality by at least 50%.) com-
pared to the control group. Based on these assumptions
and for a 5% significance level, 2-sided log-rank test of
equality of survival curves, 89 events are required dur-
ing the follow up period which corresponds to a sample
size of 536 patients randomized to ICD or amiodarone
(Fig. 1). If we want to conduct such a trial only in those
patients who have preserved LV function with an esti-
mated annual mortality of ≈5%, the calculated number
will be nearly double. We however believe that this trial
is not necessary as the bulk of evidence (see above) sup-
ports the superiority of ICD in patients who suffer from
HTVT, and there would be serious ethical consideration
in conducting such a clinical trial.
Conclusion
Despite current controversies and differences, the
available data show that CAD patients with HTVT
have a similar prognosis as more severely symptomatic
Fig. 1. Survival curves¶ during hypothetical 5 year follow up
of in a low risk group of patients (e.g. those with preserved LV
function) treated with ICD vs. amiodarone and control group∗.
(∗The annual all cause mortality assumed to be 9% in AMD
group and ICD expected to decrease all-cause mortality by 50%.
If we randomize 536 patients equally to ICD and AMD group, at
the end of three year follow up 89 events would happen and the
difference would reach to statistical significance by a 95% power.
†The calculated survival is based on 10% reduction in all-cause
mortality by AMD. ‡The calculated survival is based on 20%
reduction in all-cause mortality by AMD,¶ Note that survival
curves diverge dramatically after second year of follow up and
reach to a statistically significant difference after three years of
follow up (see above). Had the follow up been stopped after a two
years period (like AVID), the difference in mortality would have
not reached to statistical significance. This example signifies the
effect of follow up duration on assessment of treatment outcome
in ICD trials (see also: Does the ICD Benefit Change over
Time?)) AMD: Amiodarone.
VT and therefore amiodarone is not an acceptable treat-
ment in the ICD era in these patients. ICD is the pre-
ferred mode of therapy in this setting.
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